Kaiser Permanente GLP-1 Coverage 2026: What Is and Isn’t Covered

Last Updated: MARCH 2026

The landscape of GLP-1 medications for weight management continues its rapid evolution, with drugs like tirzepatide demonstrating significant efficacy. In the SURMOUNT-1 trial, tirzepatide at its highest dose (15 mg) led to a 20.9% mean weight reduction from baseline in adults with obesity or overweight, compared to 3.1% for placebo (NEJM, 2022) [1]. As these powerful medications become more integrated into chronic disease management, Kaiser Permanente members are looking ahead to 2026 to understand their coverage options. Navigating Kaiser’s formulary, prior authorization requirements, and out-of-pocket costs is critical for access to these therapies.

Kaiser Permanente, a leading integrated healthcare system, typically manages its pharmacy benefits closely, often employing a tiered formulary and strict prior authorization protocols. For 2026, members can expect a continuation of this approach, with a strong emphasis on medical necessity, documented obesity-related comorbidities, and a history of failed conservative weight management interventions.

The 2026 GLP-1 Formulary: Which Medications are Covered?

Kaiser’s formulary is dynamic, evolving based on FDA approvals, clinical evidence, cost-effectiveness, and negotiated rebates with pharmaceutical manufacturers. For 2026, the formulary for GLP-1 medications will differentiate between those indicated solely for type 2 diabetes and those approved for chronic weight management.

GLP-1s for Type 2 Diabetes (with potential for off-label weight loss)

Medications primarily indicated for type 2 diabetes, such as Ozempic (semaglutide) and Mounjaro (tirzepatide), are generally covered when prescribed for their FDA-approved indication. However, off-label use for weight loss, even in individuals with obesity, is typically not covered by insurance plans, including Kaiser, unless the plan explicitly covers anti-obesity medications and the specific drug is on formulary for that purpose.

• Ozempic (semaglutide injection): Expected to remain on formulary for type 2 diabetes.
• Rybelsus (oral semaglutide): Expected to remain on formulary for type 2 diabetes.
• Mounjaro (tirzepatide injection): Expected to remain on formulary for type 2 diabetes.

GLP-1s for Chronic Weight Management

Dedicated anti-obesity medications (AOMs) like Wegovy (semaglutide) and Zepbound (tirzepatide) are specifically approved by the FDA for chronic weight management. Coverage for these drugs depends entirely on whether an individual’s specific Kaiser health plan benefit includes coverage for AOMs. Many employer-sponsored plans and some individual plans exclude weight loss medications.

• Wegovy (semaglutide injection): Approved for chronic weight management. If AOMs are covered by your plan, Wegovy is a strong candidate for inclusion on Kaiser’s formulary.
• Zepbound (tirzepatide injection): Approved for chronic weight management. Similar to Wegovy, its coverage hinges on your plan’s specific benefit for AOMs.

Emerging Oral GLP-1 for Weight Management

The landscape is poised for an additional significant entry in 2026: an oral form of semaglutide specifically indicated for chronic weight management. While the FDA approved oral semaglutide (Rybelsus) for type 2 diabetes, a higher-dose oral semaglutide for weight loss, which demonstrated substantial efficacy in the OASIS 4 trial, is expected to be available early 2026. If approved and launched, this oral option could offer an alternative to injectables, though coverage will still depend on Kaiser’s formulary and your plan’s AOM benefit.

Expected Kaiser Permanente 2026 GLP-1 Formulary Overview (Illustrative)

Disclaimer: This table represents expected formulary status based on current trends and is illustrative. Actual Kaiser Permanente 2026 formulary details are subject to change and depend on individual plan benefits.

Prior Authorization Requirements: The Gatekeepers

Accessing GLP-1 medications through Kaiser, especially for weight management, almost universally requires prior authorization (PA). This is a process where your doctor must submit documentation to Kaiser demonstrating that the medication is medically necessary according to their specific criteria.

Typical prior authorization criteria for GLP-1s for chronic weight management (Wegovy, Zepbound, future oral AOMs) in 2026 are expected to include:

1. Diagnosis of Obesity or Overweight:
   • Body Mass Index (BMI) of 30 kg/m² or greater.
   • OR BMI of 27 kg/m² or greater with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease).
2. Exclusion of Secondary Causes: Ruling out other medical conditions or medications contributing to weight gain.
3. Prior Weight Management Efforts (Step Therapy): Documentation of participation in a comprehensive weight management program for at least six months, including diet, exercise, and behavioral modifications, without achieving adequate weight loss (e.g., less than 5% total body weight loss).
4. No Contraindications: Absence of contraindications to GLP-1s, such as personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or pancreatitis.
5. Failure of Other AOMs (Step Therapy for Meds): In some cases, Kaiser may require a trial and failure of less expensive, older generation anti-obesity medications before approving a GLP-1.

For GLP-1s prescribed for type 2 diabetes (Ozempic, Mounjaro, Rybelsus), prior authorization criteria will focus on:

1. Diagnosis of Type 2 Diabetes: Confirmation of diagnosis with relevant lab results (e.g., HbA1c).
2. Inadequate Glycemic Control: Often requires a specific HbA1c threshold (e.g., >7%) despite optimized therapy with metformin or other first-line agents.
3. Step Therapy: Failure to achieve glycemic targets on metformin or other preferred diabetes medications. Some plans may require a trial of an SGLT2 inhibitor before a GLP-1, especially if cardiovascular or renal benefits are a factor.

Your prescribing physician will be responsible for submitting the necessary documentation. Complete and accurate submissions are crucial for approval. Incomplete forms are a leading cause of denial.

What Members Pay Out of Pocket

Even with coverage, GLP-1 medications can be expensive, and member out-of-pocket costs will vary significantly based on your specific Kaiser Permanente plan design. Key cost-sharing components include:

1. Deductible: The amount you must pay out of pocket before your insurance starts to cover costs. Many plans have high deductibles that must be met before GLP-1 coverage kicks in.
2. Copayment: A fixed dollar amount you pay for a prescription after your deductible is met. GLP-1s are often placed in higher formulary tiers (e.g., Tier 3 or 4 for specialty drugs), meaning higher copayments (e.g., $50-$150+ per month).
3. Coinsurance: A percentage of the drug’s cost you pay after your deductible is met. For very expensive specialty drugs, coinsurance can result in substantial monthly costs (e.g., 20% of a $1,000 drug is $200).
4. Out-of-Pocket Maximum: The maximum amount you will pay for covered medical services and prescriptions in a plan year. Once this limit is reached, your plan pays 100% of covered costs.

Kaiser’s integrated model means pharmacy benefits are often directly linked. To ascertain your exact out-of-pocket costs, you will need to review your specific Kaiser Permanente Evidence of Coverage (EOC) or call your Member Services number.

Medicare and GLP-1 Coverage in 2026

For Kaiser Permanente Senior Advantage (Medicare Part D) members, GLP-1 coverage has distinct rules. Historically, Medicare Part D did not cover medications solely for weight loss. However, recent developments are shifting this landscape:

• Ozempic and Mounjaro for Type 2 Diabetes: These medications are covered by Medicare Part D when prescribed for type 2 diabetes, provided they are on your specific plan’s formulary and medical necessity criteria are met. They are not covered for weight loss alone.
• Wegovy for Cardiovascular Risk Reduction: In a significant policy shift, Medicare began covering Wegovy for individuals with established cardiovascular disease and obesity or overweight to reduce the risk of major adverse cardiovascular events (MACE). This coverage, stemming from the SELECT trial, represents a crucial expansion beyond diabetes.
• CMS GLP-1 Payment Demonstration (July 2026 Bridge): Certain Medicare Part D plans may participate in a “CMS GLP-1 Payment Demonstration” starting July 2026, which could provide a bridge for broader GLP-1 coverage for weight management for specific plans and beneficiaries. Medicare members with Kaiser plans should verify their plan’s participation by contacting member services during Open Enrollment (October 15-December 7, 2025, for 2026 coverage). If your Kaiser Part D plan does not participate, switching plans during Open Enrollment might be an option.
• Medicare Drug Price Negotiations: In January 2025, the Centers for Medicare & Medicaid Services (CMS) selected Ozempic, Rybelsus, and Wegovy for its second round of Medicare drug price negotiations [3]. The Medicare-negotiated prices, effective in 2027, are projected to be substantially lower, at $274 for a 30-day supply for these drugs. While these negotiated prices impact 2027, the negotiation process itself signals increasing access and affordability on the horizon.

What to Do If Your GLP-1 is Denied

A denial from Kaiser for a GLP-1 prescription, while frustrating, is not necessarily the final word. There are established processes for appeal:

1. Internal Appeals: The first step is typically an internal appeal. Your doctor, in collaboration with you, will submit additional medical documentation or a letter of medical necessity to Kaiser, explaining why the medication is clinically appropriate and meets their criteria, or why your specific circumstances warrant an exception. This may involve highlighting failed previous treatments, unique health conditions, or severe comorbidities.
2. External Review: If the internal appeal is denied, you may be eligible for an external review. This involves an independent third party, often chosen by your state’s Department of Managed Health Care or equivalent regulatory body, reviewing your case and Kaiser’s decision. Their decision is binding on Kaiser